Arrowhead Research (ARWR) Files for Clearance to Begin Phase 1/2 Study of ARC-521
Tweet Send to a Friend
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR), recently filed a regulatory submission in New Zealand to begin a Phase 1/2 clinical trial ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
